MP 601205Alternative Names: MP-601205; MPI-601,205
Latest Information Update: 16 Nov 2011
At a glance
- Originator Mpex Pharmaceuticals
- Mechanism of Action Membrane protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections